Quent Capital’s Puma Biotechnology PBYI Stock Holding History

Quent Capital’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-143	Closed	–	–	1354
2022 Q3	$0	Hold	143	–	–	﹤0.01%	1265
2022 Q2	$0	Hold	143	–	–	﹤0.01%	1275
2022 Q1	$0	Buy	+143	New	+$370	﹤0.01%	1311

Other funds holding PBYI

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

ACM

Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

HIM

Hillsdale Investment Management Toronto, Ontario, Canada $4.39B AUM 72.96% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Quent Capital's PBYI Position: Q4 2022 in Review

Quent Capital sold out of Puma Biotechnology (PBYI) in Q4 2022, closing a stake of 143 shares.

Quent Capital first reported a position in PBYI in Q1 2022 and held it in 3 quarters. The position peaked at $0 in Q3 2022. 88 funds tracked by Wall St. Rank hold PBYI as of Q4 2022.

Quent Capital reported no remaining Puma Biotechnology position as of Q4 2022 after selling out during the quarter.
Quent Capital sold 143 Puma Biotechnology shares in Q4 2022.
Quent Capital first reported a position in Puma Biotechnology in Q1 2022 and held it in 3 quarters.
Quent Capital's Puma Biotechnology position peaked at $0 in Q3 2022.
88 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2022.

Based on Quent Capital's 13F filing for Q4 2022, filed 19 Jan 2023.